Andrew G. Iwach, MD

Associate Clinical Professor
University of California, San Francisco
San Francisco, California

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Andrew G. Iwach, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Belkin Lasers, and OMIC. Shareholder: Eyenovia

J. Michael Jumper, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: EyeBio. Speakers Bureau: Dutch Ophthalmic Research. Grant/Research Support: Genentech, Novartis, Regeneron, RegenXBio, and Boehringer Ingelheim. Shareholder: EyeBio and Covalent Medical

Joshua D. Stein, MD, MS has had a financial relationship or affiliation with the following ineligible companies in the form of Grant / Research Support: AbbVie, Janssen and Ocular Therapeutix

Kuldev Singh, MD, MPH has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Apellis, Belkin, Centricity, Ellios, Glaukos, Ivantis, iCare, Novartis, Ocular Therapeutix, Oculis, RegenxBio, Santen and Sight Sciences.

L. Jay Katz, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Glaukos. Speakers Bureau: Allergan, Shareholder: Glaukos, Mati Pharma, and Olleyes.

Leon W. Herndon, Jr., MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Balance Ophthalmics, Sight Sciences, New World Medical, Glaukos, and Ocular Therapeutix

Oluwatosin U. Smith, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie, Alcon, Bausch + Lomb, Allergan, Iridex, Santen, New World Medical, Glaukos, and Iris Vision. Speaker’s Bureau: Aerie, Bausch + Lomb, and Allergan. Shareholder: Nova Eye Medical and Olleyes

Robert L. Stamper, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Shareholder: Inject Sense

Ronald L. Fellman, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: BVI and Sanoculis. Grant/Research Support: Olleyes. Shareholder: Olleyes, Sanoculis, and Nova Eye Med.

Ruth D. Williams, MD has had no financial relationships or affiliations with ineligible companies.

Shan Lin, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Iridex Corporation, Bausch + Lomb, Dompe,  ArcScan, and Santen Pharmaceuticals. Speakers Bureau: Iridex Corporation.

Sunita Radhakrishnan, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Netra Systems

Terri Pickering, MD has had no financial relationships or affiliations with ineligible companies.

Ying Han, MD, PhD has had no financial relationships or affiliations with ineligible companies.

Iqbal Ike K. Ahmed, MD FRCSC has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aequus, Ace Vision, Aerie Harmaceuticals, Akorn, Alcon, Allergan, Aquea Health, ArcScan, Avellino Lab USA, Avisi, Bausch Health, Beaver Visitec, Belkin Vision, Beyeonics, Bionode, Carl Zeiss Meditec, Centricity Vision, CorNeat Vision, Custom Surgical, Elios Vision, ElutiMed, Equinox, eyeFlow, EyedMed, EyeQ Technologies, Exhaura Limited, Genentech,Glaukos, Gore, Heine, Heru, Hexiris Pharma, Iantrek, InjectSense, Iridex, iStar, Ivantis, Johnson & Johnson, Labtician Thea, LayerBio, Leica Microsystems, Life Long Vision, Long Bridge Medical, MicroOptx, MST Surgical, Myra Vision, New World Medical, NovaEye, Ocular Instruments, Ocular Therapeutix, Oculo, Oculus Surgical, Omega Ophthalmics, PolyActiva, PulseMedica, Radiance Thereapeutics, Radius, Rheon Medical, Ripple Therapeutics, Samsara Vision, Sanoculis, Santen, Sight Sciences, Smartlens, Stroma, Thea Pharma, TFS Health Science, ViaLase, Visus Therapeutics, Vizzario, VSY Biotechnology, and Zilia Inc. Grant/Research Support: Aerie Pharmaceuticals, Alcon, Allergan, Bionode, Glaukos, iCare, Ivantis, Johnson & Johnson, New World Medical, and Santen. Shareholder: Alcon, Allergan, Carl Zeiss Meditec, Johnson & Johnson, and MST Surgical.

The Evolve and Glaucoma Research and Education Group staff, planners and peer reviewer have no financial relationships with ineligible companies.